Eli Lilly and Company LLY Analyst Ratings

18 ratings from Wall Street analysts · latest analyst action Feb 10, 2026

Analyst Ratings
Buy Consensus target withheld — no analyst update in over 90 days showing 18 ratings
Latest analyst action Feb 10, 2026
LLY
Resumed
2026-01-07
UBS
RatingBuy
From
Target$1250
From
Upgrade
2025-12-16
Daiwa Securities
RatingBuy
FromNeutral
Target$1230
From
Reiterated
2025-12-15
Goldman
RatingBuy
From
Target$1145
From$951
Reiterated
2025-12-15
BofA Securities
RatingBuy
From
Target$1268
From$1286
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From
Target$1165
From
Upgrade
2025-11-10
Leerink Partners
RatingOutperform
FromMarket Perform
Target$1104
From
Reiterated
2025-10-20
BMO Capital Markets
RatingOutperform
From
Target$930
From$840
Downgrade
2025-09-17
Berenberg
RatingHold
FromBuy
Target$830
From
Upgrade
2025-08-27
HSBC Securities
RatingHold
FromReduce
Target$700
From
Downgrade
2025-08-18
Daiwa Securities
RatingNeutral
FromOutperform
Target$700
From
Downgrade
2025-08-07
Leerink Partners
RatingMarket Perform
FromOutperform
Target$715
From
Downgrade
2025-04-28
HSBC Securities
RatingReduce
FromBuy
Target$700
From$1150
Initiated
2025-04-22
Cantor Fitzgerald
RatingOverweight
From
Target$975
From
Resumed
2024-12-10
BofA Securities
RatingBuy
From
Target$997
From
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From
Target$1000
From
Initiated
2024-10-17
Bernstein
RatingOutperform
From
Target$1100
From
Resumed
2024-09-13
Citigroup
RatingBuy
From
Target$1060
From
Upgrade
2024-08-12
Deutsche Bank
RatingBuy
FromHold
Target$1025
From